Title of Invention

POLYPHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF HYPERTENSION

Abstract The present invention relates to a polypharmaceutical composition for the treatment of hypertension comprising extracts of the following: Ingredients Quantity by parts Rauwolfia Serpentina : 50-75 mg. Juniper communis : 0.5-1.5 mg Zeamays stigma : 40-60 mg Cicer arietinum husk : 45-65 mg Hordeam Vulgare : 20-35 mg Shora Kalmi : 1.5-2.5 mg
Full Text This invention relates to a polypharmaceutical composition for the treatment
of hypertension.
BACKGROUND:
Hypertension is the commonest cardiovascular disorder, all over the world
including India, where about 6-15 % of the adults in different surveys have
been shown to be suffering from hypertension (Manchanda,1985).
It is not easy to define hypertension because blood pressure (BP) is not a
constant figure and shows fluctuations during 24 hours of the day and night.
Moreover, even within the so called "normal" range, the lower the BP the
better it is in the long run. There is no sharp cut off line between "normals"
and hypertensive and BP varies with age.
However WHO has defined hypertension in adults as BP equal to or greater
then 160/95 mm Hg. Normal BP is 140/90 mm Hg or lower. Blood pressure
between 140/90 and 160/95 mm Hg is defined as borderline hypertension.
Isolated systolic hypertension (especially prevalent in the elderly) exists
when the systolic BP is 160 mm Hg or more and diastolic BP is less then 95
mm Hg. Labile Hypertension exists in a person (who is not on anti-
hypertensive medication) when the BP sometimes is in the normal age
(equal to or 140/90 mm Hg) and sometimes shows values in the
hypertensive range. A single high blood pressure reading should not be
ignored because it has been shown that a casual reading of high BP is also
associated with higher risk .It is suggested that the average of BP recordings
of 3 visits and not the lowest of the 3 values should be taken to guide the
therapy. Criteria of high BP are different in case of children depending upon
age.
A few simple precautions are necessary for accurate measurement of BP.
Standard cuf£ 12.5 cm wide and 30 cm long attached to a well calibrated
mercury manometer gives the most accurate estimation of BP in most
average adults. Bigger cuffs (14-15cm wide) are needed for the obese and
smaller cuffs are needed for children in order to measure the BP correctly.
The diastolic BP is generally recorded at a point when the sounds on
auscultation over the brachial artery completely disappear (Korotkoff phase
V). However, in certain situations where the diastolic BP is low (e.g. aortic
incompetence, pregnancy, anemia etc, the muffling of sounds (korotkoff
phase IV) is considered to represent the diastolic blood pressure (Frohlich
1981,kannel 1974 and 1980; Manchanda 1985dickering 1972;WHO 1978).
It is axomatic that the prefect antihypertensive drug has not yet been
discovered .The reasons for this are threefold. First, the heterogenecitv or
hypertension as a disease (Folkow 1982). Second, the heterogenecitv of the
patient (Guyton et al. 1974) since the drug responses are governed by two
main variables and pharmaokinetics. Third, the heterogenecitv of the drugs
since treatment should continue over the years. Our understanding of the
fundamental nature of raised blood pressure however has improved and in
the wake of this, new drugs have been invented. A second reason to search
for new drug is dissatisfaction with existing agents. The adverse reaction
profile of drugs especially those used to treat mild asymptomatic
hypertension, is a prime arbiter of how and when they will be prescribed and
taken. Long-term use of thiazides may increase incidence of coronary artery
disease.
The object of this invention is to develop a polypharmaceutical composition
consisting of herbs, which could treat the essential hypertension effectively
without producing any toxic effects in the major coronary organs of the
body.
To achieve the objective, studies were carried out for the treatment of
essential hypertension while managing coronary disorders. This invention,
therefore, provides for a polypharmaceutical composition for the treatment
of hypertension comprising the following:
Ingredients Quantity by parts
Rauwolfia Serpentina 50-75 mg.
Juniper communis 0.5-1.5 mg
Zeamays stigma : 40-60 mg
Cicer arietinum husk 45-65 mg
Hordeum Zulgare 20-35 mg
ShoraKalmi 1.5-2.5 mg
Predetermined quantity of fillers and binders may be mixed to the said
composition.
The extracts of the herbal ingredients are prepared separately with Ethyl
Alcohol and distilled water.
The extracts of the aforesaid ingredients are prepared preferably in ethyl
alcohol to get the maximum yield and active constituents for the treatment of
essential hypertension.
The extract of Rauwolfia Serpentina is prepared in alcohol. The extracts of
Juniper communis, Zeamays stigma and Cicer arietinum husk is an aqueous
extract.
The instant invention will now be described with reference to the following
examples:
Example 1:
The ingredients are mixed in the following proportions:
Ingredients Quantity by parts
Rauwolfia Serpentina 65 mg
Juniper communis 0.8 mg
Zea maystigma 55 mg
Cicer arietinum husk 54 mg
Hordeum Zulgare 30 mg
Shora Kalmi 1 7 mg
Pre-determined quantity of binders and fillers are added at room temperature
and the said mixture is homogenized to get uniform mixing of the
composition.
DOSAGE:
The doses recommended for the treatment of the disease, one-two tablets
three times a day or more as advised by the physician.
Patients having diastolic BP > 120 mm Hg - 6 tablets/day
Patients having diastolic BP > 100 mm Hg but tablets/day
Patients having diastolic BP>90 mm Hg but > 100 mm Hg - 2 tablets/day
Mean: ± S.E
The data presented in Table 1 reveals about the response of hypertensive
patients to a dosage of 2 tablets per day when the duration of treatment was
for 4-28 days (group A), 1-6 months (group B) and 8-18 months (group C).
In a patient after having the treatment, the systolic blood pressure was
reduced by 16.49%, 21.68 % and 17.28 % and the diastolic pressure by
14.04 %, 21.15% and 16.96 % in group A, B and C patients respectively.
The mean systolic blood pressure before treatment was in the range of
151.12 to 173.63 mm Hg which was decreased to 125-145 mm Hg.
Similarly, the mean diastolic blood pressure before treatment was 106 to 112
which decreased to 88.12 to 94 mm Hg in the respective groups.
The data presented in Table 2 reveals about the response of hypertensive
patients to a dosage of 4 tablets per day when the duration of treatment was
for 1-27 days (group A), 1- 1 Vz months (group B), 2-11 months (group C)
and 1-5 lA years (Group D). In a patient after having the treatment, the
systolic blood pressure was reduced by 18.24 %, 17.56 %, 20.03 % and
12.69 % in group A,B,C and D respectively. The diastolic pressure was
reduced by 13.50 %, 12.74%, 19.54% and 20.90 % in group A, B, C and D
patients respectively. The mean systolic blood pressure before treatment was
in the range of 157.55 to 174.18 mm Hg which was decreased to 136.77 to
139.29 mm Hg. Similarly, the mean diastolic blood pressure before
treatment was 106 to 113mm Hg which decreased to 88.85 to 94.06 mm Hg
in the respective groups.
The data presented in Table 3 reveals about the response of hypertensive
patients to a dosage of 6 tablets per day when the duration of treatment was
for 2-30 days (group A), 1-6 months (group B), 1-3 years (group C) and 4-7
years(Group D). In the patient after having the treatment, the systolic blood
pressure was reduced by 15.28%, 22.18%, 23.48%, and 22.95 % in group
A,B,C and D respectively. The diastolic pressure was reduced by 19.31 %.
27.74%, 25.17% and 26.36 % in group A, B, C and D patients respectively.
The mean systolic blood pressure before treatment was in the range of
188.11 to 199.2 mm Hg which was decreased to 143.94 to 163.11 mm Hg.
Similarly, the mean diastolic blood pressure before treatment was 124.27 to
127.6 mm Hg which decreased to 92.25 to 100.27 mm Hg in the respective
groups.
We claim:
1. A polypharmaceutical composition for the treatment of hypertension
comprising the following:
Ingredients Quantity by parts
Rauwolfia Serpentina 50-75 mg.
Juniper communis 0.5-1.5 mg
Zeamays stigma 40-60 mg
Cicer arietinum husk 45-65 mg
Hordeum Zulgare 20-35 mg
ShoraKalmi 1.5-2.5 mg
2. A composition as claimed in claim 1 further comprising predetermined
quantity of fillers and binders.
3. A composition as claimed in claim 1 wherein the proportions in which
the ingredients are :
Rauwolfia Serpentina 65 mg
Juniper Communis : 0.8 mg
Zeamays stigma 55 mg
Cicer arietinum husk 54 mg
Hordeum Zulgare 30 mg
Shora Kalmi 1.7 me
4. A polypharmaceutical composition for the treatment of hypertension
substantially as herein described with reference to the foregoing
examples.


The present invention relates to a polypharmaceutical composition for the
treatment of hypertension comprising extracts of the following:
Ingredients Quantity by parts
Rauwolfia Serpentina : 50-75 mg.
Juniper communis : 0.5-1.5 mg
Zeamays stigma : 40-60 mg
Cicer arietinum husk : 45-65 mg
Hordeam Vulgare : 20-35 mg
Shora Kalmi : 1.5-2.5 mg

Documents:

823-cal-1999-abstract.pdf

823-cal-1999-claims.pdf

823-CAL-1999-CORRESPONDENCE.pdf

823-cal-1999-description (complete).pdf

823-cal-1999-examination report.pdf

823-cal-1999-form 1.pdf

823-cal-1999-form 18.pdf

823-cal-1999-form 2.pdf

823-cal-1999-form 3.pdf

823-cal-1999-granted-abstract.pdf

823-cal-1999-granted-claims.pdf

823-cal-1999-granted-correspondence.pdf

823-cal-1999-granted-description (complete).pdf

823-cal-1999-granted-examination report.pdf

823-cal-1999-granted-form 1.pdf

823-cal-1999-granted-form 18.pdf

823-cal-1999-granted-form 2.pdf

823-cal-1999-granted-form 3.pdf

823-cal-1999-granted-others.pdf

823-cal-1999-granted-reply to examination report.pdf

823-cal-1999-granted-specification.pdf

823-CAL-1999-OTHERS.pdf

823-cal-1999-pa.pdf

823-cal-1999-reply to examination report.pdf

823-cal-1999-specification.pdf


Patent Number 244355
Indian Patent Application Number 823/CAL/1999
PG Journal Number 49/2010
Publication Date 03-Dec-2010
Grant Date 02-Dec-2010
Date of Filing 05-Oct-1999
Name of Patentee MR. ABDUL MUEED
Applicant Address 1-A, SANDAL STREET, CALCUTTA
Inventors:
# Inventor's Name Inventor's Address
1 MR. ABDUL MUEED 1-A, SANDAL STREET, CALCUTTA-700 016
PCT International Classification Number A61K
PCT International Application Number N/A
PCT International Filing date
PCT Conventions:
# PCT Application Number Date of Convention Priority Country
1 NA